Genitourinary Cancers Symposium (ASCO GU) | Conference

Cabozantinib Improves PFS Across High-Risk RCC Subgroups

January 4th 2016

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

Dr. Scholz on Using Abiraterone in mCRPC

March 4th 2015

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

March 2nd 2015

Naomi B. Haas, MD, associate professor, Abramson Cancer Center of the University of Pennsylvania, discusses the phase III ASSURE trial which looks at sorafenib or sunitinib for locally advanced renal cell carcinoma (RCC).

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

March 2nd 2015

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC

March 2nd 2015

A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

March 2nd 2015

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Second-Line Ramucirumab Plus Docetaxel in Urothelial Cancer Improves Progression-Free Survival

February 28th 2015

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

Pazopanib/Paclitaxel Combination Demonstrates Activity in Relapsed/Refractory Urothelial Cancer

February 28th 2015

In patients evaluable for treatment response, the ORR with the combination was 50%, with 11% having a CR.

Dr. Ryan on the Long Term Safety of Abiraterone Use

February 27th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27th 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

February 27th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer

February 27th 2015

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

Abiraterone OS Benefit Prolonged After Crossover Adjustment in mCRPC

February 27th 2015

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

No Survival Benefit From Adding Docetaxel to ADT in Hormone-Sensitive Prostate Cancer

February 27th 2015

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

Immunointensification May Favorably Alter Survival in mCRPC

February 27th 2015

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

February 26th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Dr. McKay on Statin Use in Patients With mRCC

February 26th 2015

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Analysis Shows Increase in Higher-Risk Prostate Cancers

February 23rd 2015

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer

February 23rd 2015

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

Sorafenib, Sunitinib Fail in Phase III Adjuvant RCC Trial

February 23rd 2015

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.